



PRESS RELEASE

18 November 2008

ENIGMA DIAGNOSTICS LAUNCHES FIELD LABORATORY (FL) SYSTEM, FULLY AUTOMATED REAL-TIME PCR FOR IN-FIELD TESTING

Porton Down, UK – Enigma Diagnostics, the decentralised and point-of-care molecular diagnostics company, announces the launch of its upgraded version of Enigma FL at the XIth International CBRN Defence Symposium in Shrivenham, UK.

Enigma FL is a fully automated, real-time PCR (polymerase chain reaction detection) system designed for in-field testing applications by veterinarians, first responders and military personnel. It combines the speed and sensitivity of real-time PCR with the simplicity needed for field-based tests.

Portable and completely self-contained, every aspect of its operation has been fully automated to provide ultra-rapid, laboratory-standard results when used in the field. The process, from collection of the raw sample (e.g., soil, water, powder, blood) to delivery of an unequivocal end result, can take less than 30 minutes.

The new FL instrument incorporates solid state, multiplexing optics and dye deconvolution algorithms and is launched with freeze dried assays provided by Applied Biosystems. The assay panel will include tests for infectious diseases in livestock (e.g., avian influenza) and tests for biothreat agents (e.g., Anthrax).

-ENDS-

Contacts

UK Contact:

Enigma Diagnostics

Deborah Cordingley

deborah.cordingley@enigmadiagnostics.com

+44 1980 590131

US Contact:

Richard Lewis Communications, Inc.

212-827-0020

Gregory Tiberend – Media

gtiberend@rlcinc.com

Megan Dubrowski - Media

mdubrowski@rlcinc.com



PRESS RELEASE

Cecelia Heer - Investors
cheer@rlcinc.com

Notes to editors:

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive licence from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com